Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
Kornblith AB, Herndon JE 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC. Kornblith AB, et al. Among authors: ellerton j. J Clin Oncol. 2002 May 15;20(10):2441-52. doi: 10.1200/JCO.2002.04.044. J Clin Oncol. 2002. PMID: 12011121 Clinical Trial.
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Silverman LR, et al. Among authors: ellerton j. J Clin Oncol. 2002 May 15;20(10):2429-40. doi: 10.1200/JCO.2002.04.117. J Clin Oncol. 2002. PMID: 12011120 Clinical Trial.
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
Niell HB, Herndon JE 2nd, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR; Cancer and Leukemia Group. Niell HB, et al. Among authors: ellerton j. J Clin Oncol. 2005 Jun 1;23(16):3752-9. doi: 10.1200/JCO.2005.09.071. J Clin Oncol. 2005. PMID: 15923572 Clinical Trial.
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.
Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS; Cancer and Leukemia Group B 89803. Meyerhardt JA, et al. J Clin Oncol. 2008 Sep 1;26(25):4109-15. doi: 10.1200/JCO.2007.15.6687. J Clin Oncol. 2008. PMID: 18757324 Free PMC article. Clinical Trial.
Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA, Herndon JE 2nd, Hollis DR, Ellerton J, Langleben A, Richards F 2nd, Green MR. Miller AA, et al. Among authors: ellerton j. J Clin Oncol. 1995 Aug;13(8):1871-9. doi: 10.1200/JCO.1995.13.8.1871. J Clin Oncol. 1995. PMID: 7636529 Clinical Trial.
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D; Cancer and Leukemia Group B. Romanus D, et al. J Pain Symptom Manage. 2012 Feb;43(2):205-17. doi: 10.1016/j.jpainsymman.2011.09.001. Epub 2011 Nov 21. J Pain Symptom Manage. 2012. PMID: 22104618 Free PMC article. Clinical Trial.
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
Baer MR, George SL, Sanford BL, Mrózek K, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. Baer MR, et al. Leukemia. 2011 May;25(5):800-7. doi: 10.1038/leu.2011.9. Epub 2011 Feb 15. Leukemia. 2011. PMID: 21321569 Free PMC article.
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.
Stinchcombe TE, Hodgson L, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Niell HB, Atkins JN, Akerley W, Green MR, Vokes EE; Cancer and Leukemia Group B. Stinchcombe TE, et al. J Thorac Oncol. 2009 Sep;4(9):1117-25. doi: 10.1097/JTO.0b013e3181b27b33. J Thorac Oncol. 2009. PMID: 19652624 Free PMC article.
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD; Cancer and Leukemia Group B (CALGB). Langer C, et al. Blood. 2008 Jun 1;111(11):5371-9. doi: 10.1182/blood-2007-11-124958. Epub 2008 Mar 31. Blood. 2008. PMID: 18378853 Free PMC article. Clinical Trial.
67 results